Abstract: A method for determining the degree of soiling of an air filter, in particular of an air filter in the interior space of motor vehicle, in which air to be purified is directed across at least one filter body in a predetermined direction of flow. An indirect pressure measurement takes place before and after the at least one filter body in the predefined direction of flow. An apparatus for determining the degree of soiling of an air filter is also provided, having at least one filter body as well as an airflow chamber connected upstream of the filter body and an airflow chamber connected downstream of the filter body. An indirect pressure measurement device is allocated to the airflow chamber connected upstream of the filter body and to the airflow chamber connected downstream of the filter body.

Abstract: Artifacts due to delivery of an electrical signal (e.g., for neural stimulation or nerve block) can be eliminated from neural recordings. An activating stimulus (AS) can be applied by at least one neural electrode located at a first position within a body or a preparation proximal to a neural structure. The AS includes an electrical waveform configured to affect (e.g., stimulate or block) conduction in the neural structure. A counter stimulus (CS) can be applied by at least one electrode located at a second position within the body or the preparation remote from the neural structure. The CS includes an electrical waveform configured with a timing parameter and an amplitude parameter selected based on a feature of the AS. Artifacts due to the AS can be blocked by the CS during the neural recordings.

Abstract: The occurrence of negative consequences (e.g., painful tetanic muscle contractions) associated with the onset response associated with kilohertz frequency alternating current (KHFAC) electrical nerve block can be reduced by fatiguing a muscle (through depletion of neurotransmitters at the neuromuscular junction, within a second) before applying KHFAC electrical nerve block to a nerve associated with the muscle. The nerve can first be stimulated with an electrical signal for a first time period to fatigue the muscle. Then, immediately following the first time period (while the muscle is fatigued), a blocking electrical signal (e.g., a kilohertz frequency alternating current waveform) can be applied to the nerve to create a localized nerve block.

Abstract: The invention is directed towards stable formulations of 5,10-methylene-(6R)-tetrahydrofolic acid and its hemisulfate salt as well as pharmaceutical compositions and uses thereof in therapy, preferably chemotherapy.

Abstract: The invention is directed towards stable formulations of 5,10-methylene-(6R)-tetrahydrofolic acid and its hemisulfate salt as well as pharmaceutical compositions and uses thereof in therapy, preferably chemotherapy.

Abstract: The present invention is directed towards the hemisulfate salt of 5,10-methylene-(6R)-tetrahydrofolic acid, preferably in substantially crystalline form, as well as pharmaceutical compositions and uses thereof in therapy, preferably chemotherapy.

Abstract: The occurrence of negative consequences (e.g., painful tetanic muscle contractions) associated with the onset response associated with kilohertz frequency alternating current (KHFAC) electrical nerve block can be reduced by fatiguing a muscle (through depletion of neurotransmitters at the neuromuscular junction, within a second) before applying KHFAC electrical nerve block to a nerve associated with the muscle. The nerve can first be stimulated with an electrical signal for a first time period to fatigue the muscle. Then, immediately following the first time period (while the muscle is fatigued), a blocking electrical signal (e.g., a kilohertz frequency alternating current waveform) can be applied to the nerve to create a localized nerve block.

Abstract: The invention is directed towards stable formulations of 5,10-methylene-(6R)-tetrahydrofolic acid and its hemisulfate salt as well as pharmaceutical compositions and uses thereof in therapy, preferably chemotherapy.

Abstract: The invention is directed towards stable formulations of 5,10-methylene-(6R)-tetrahydrofolic acid and its hemisulfate salt as well as pharmaceutical compositions and uses thereof in therapy, preferably chemotherapy.

Abstract: The invention is directed towards stable formulations of 5,10-methylene-(6R)-tetrahydrofolic acid and its hemisulfate salt as well as pharmaceutical compositions and uses thereof in therapy, preferably chemotherapy.

Abstract: The invention is directed towards stable formulations of 5,10-methylene-(6R)-tetrahydrofolic acid and its hemisulfate salt as well as pharmaceutical compositions and uses thereof in therapy, preferably chemotherapy.

Abstract: The present invention is directed towards the hemisulfate salt of 5,10-methylene-(6R)-tetrahydrofolic acid, preferably in substantially crystalline form, as well as pharmaceutical compositions and uses thereof in therapy, preferably chemotherapy.

Abstract: The present invention is directed to a novel methods and compositions for the therapeutic intervention in hyperphenylalaninemia. More specifically, the specification describes methods and compositions for treating various types of phenylketonurias using compositions comprising BH4. Combination therapies of BH4 and other therapeutic regimens are contemplated.

Abstract: The invention is directed towards stable formulations of 5,10-methylene-(6R)-tetrahydrofolic acid and its hemisulfate salt as well as pharmaceutical compositions and uses thereof in therapy, preferably chemotherapy.

Abstract: The present invention is directed to a novel methods and compositions for the therapeutic intervention in hyperphenylalaninemia. More specifically, the specification describes methods and compositions for treating various types of phenylketonurias using compositions comprising BH4. Combination therapies of BH4 and other therapeutic regimens are contemplated.

Abstract: The invention is directed towards stable formulations of 5,10-methylene-(6R)-tetrahydrofolic acid and its hemisulfate salt as well as pharmaceutical compositions and uses thereof in therapy, preferably chemotherapy.

Abstract: The invention is directed towards stable formulations of 5,10-methylene-(6R)-tetrahydrofolic acid and its hemisulfate salt as well as pharmaceutical compositions and uses thereof in therapy, preferably chemotherapy.

Abstract: The present invention is directed to a novel methods and compositions for the therapeutic intervention in hyperphenylalaninemia. More specifically, the specification describes methods and compositions for treating various types of phenylketonurias using compositions comprising BH4. Combination therapies of BH4 and other therapeutic regimens are contemplated.

Abstract: The present invention is directed to a novel methods and compositions for the therapeutic intervention in hyperphenylalaninemia. More specifically, the specification describes methods and compositions for treating various types of phenylketonurias using compositions comprising BH4. Combination therapies of BH4 and other therapeutic regimens are contemplated.

Abstract: The present invention is directed towards the hemisulfate salt of 5,10-methylene-(6R)-tetrahydrofolic acid, preferably in substantially crystalline form, as well as pharmaceutical compositions and uses thereof in therapy, preferably chemotherapy.